Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial

Gene Therapy
S MulvihillD Kirn

Abstract

Novel therapies are needed for locally advanced pancreatic carcinoma. ONYX-015 (dl1520) is an E1B-55 kDa region-deleted adenovirus that selectively replicates in and lyses tumor cells with abnormalities in p53 function (eg gene mutation). We carried out a phase I dose escalation study of ONYX-015 in patients with unresectable pancreatic cancer. ONYX-015 was administered via CT-guided injection (n = 22 patients) or intraoperative injection (n = 1) into pancreatic primary tumors every 4 weeks until tumor progression. Interpatient dose escalation was carried out with at least three patients per dose level from 10(8) p.f.u. up to the 10(11) p.f.u. dose level (two patients treated at this dose). The majority of patients had abnormally low cellular immunity (CD4 counts and hypersensitivity skin testing). Injection of ONYX-015 into pancreatic carcinomas was well-tolerated. Mild, transient pancreatitis was noted in only one patient. Dose-escalation proceeded to the highest dose level. Neutralizing antibodies rose post-treatment in all patients. After injection, ONYX-015 was detectable in the blood 15 min later, but not between 1 and 15 days later. Viral replication was not documented, however, in contrast to trials in other tumor types...Continue Reading

References

Dec 1, 1991·British Journal of Cancer·C M BartonR C Williamson
Mar 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·H S GinsbergG A Prince
Aug 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·H S GinsbergG A Prince
May 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·H S GinsbergG A Prince
Apr 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·F ChangK Syrjänen
Jun 21, 1994·Proceedings of the National Academy of Sciences of the United States of America·J F EngelhardtJ M Wilson
Jun 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H A BurrisD D Von Hoff
Apr 5, 2000·The Journal of Clinical Investigation·D H Kirn

❮ Previous
Next ❯

Citations

Aug 30, 2007·Cancer Chemotherapy and Pharmacology·Izuru WatanabeAkimasa Nakao
May 26, 2005·Current Gastroenterology Reports·Christopher M HalloranJohn P Neoptolemos
Jun 21, 2012·Pathology Oncology Research : POR·Md ZeyaullahArif Ali
Feb 20, 2004·Current Surgery·Pedro J Ramírez, Selwyn M Vickers
Mar 26, 2003·Seminars in Cancer Biology·Irina V LebedevaPaul B Fisher
Jun 17, 2011·Expert Reviews in Molecular Medicine·Sonia WennierGrant McFadden
Mar 26, 2011·Cancer Gene Therapy·R M Eager, J Nemunaitis
May 29, 2013·Molecular Therapy : the Journal of the American Society of Gene Therapy·Soraya BravoOsvaldo L Podhajcer
Jan 30, 2007·Nature Clinical Practice. Oncology·Ta-Chiang LiuDavid Kirn
Jun 7, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Svend O FreytagJae Ho Kim
Nov 22, 2005·Oncogene·Manish Aghi, Robert L Martuza
Nov 22, 2005·Oncogene·J Michael MathisDavid T Curiel
Feb 8, 2003·DNA and Cell Biology·Chooi May LaiP Elizabeth Rakoczy
Feb 17, 2005·Pancreas·Alexander L ShifrinSteven E Raper
Mar 16, 2004·Gut·N R Lemoine, I A McNeish
Feb 19, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stephan LeitnerGunnel Halldén
May 18, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jay D NaikJohn D Chester
May 5, 2009·The Journal of Clinical Investigation·Yaohe WangNick Lemoine
Sep 1, 2008·Therapeutic Advances in Gastroenterology·Elizabeth C Verna, Vasudha Dhar
Jul 4, 2003·Annals of Surgical Oncology·John T Mullen, Kenneth K Tanabe
Mar 25, 2006·Future Oncology·Dawn E PostErwin G Van Meir
May 3, 2002·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Akseli Hemminki, Ronald D Alvarez
Jul 14, 2010·Future Oncology·Han Hsi Wong, Nicholas R Lemoine
Mar 19, 2009·World Journal of Gastroenterology : WJG·Michael-A van GeerPiter J Bosma
Jun 13, 2009·World Journal of Gastroenterology : WJG·Michael A van GeerPiter J Bosma
Apr 23, 2013·Gastroenterology Research and Practice·Lawrence A ShirleyJon P Walker
Mar 28, 2013·Diagnostic and Therapeutic Endoscopy·Rei SuzukiManoop S Bhutani
Mar 25, 2006·Future Oncology·Daniel T ReinDavid T Curiel
Jun 21, 2014·Future Oncology·Meaghan L KhanMitesh J Borad
Apr 26, 2007·Molecular Therapy : the Journal of the American Society of Gene Therapy·Marxa L FigueiredoLily Wu
Nov 23, 2010·Expert Review of Vaccines·Patrycja J Lech, Stephen J Russell
Apr 13, 2007·Expert Review of Anticancer Therapy·J-Matthias Löhr
Aug 23, 2005·Expert Review of Anticancer Therapy·Robert F Wong, Manoop S Bhutani
May 31, 2002·Expert Opinion on Investigational Drugs·Walter H GünzburgBrian Salmons
Jan 15, 2015·Expert Opinion on Biological Therapy·Hans Martin SinghApostolia M Tsimberidou
May 25, 2004·Expert Opinion on Biological Therapy·Kirsi Saukkonen, Akseli Hemminki

❮ Previous
Next ❯

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.